Telavant, Inc. clinical trials
Acquired by Hoffmann-La Roche, Dec 14, 2023 · source ↗
The registry lists 4 studies whose lead sponsor is Telavant, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2023.
- 4studies on the registry
- 0open to participants now
Before and after it joined Hoffmann-La Roche
- First submitted before Telavant, Inc. became part of Hoffmann-La Roche
- 4
- First submitted after Telavant, Inc. became part of Hoffmann-La Roche
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Telavant, Inc.’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- 0 open · 3
All 4 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Completed375%
- Stopped early125%
Over the years
- 113
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Telavant, Inc.4 studies
Something wrong with this grouping? Tell us on the Hoffmann-La Roche page.
Studies
Recruiting first, then most recently updated. Showing 4 of 4. All Hoffmann-La Roche studies →
- Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.CompletedNCT02840721Phase 2
Sponsor listed in the registry: Telavant, Inc. · First submitted before Telavant, Inc. became part of Hoffmann-La Roche
- Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's DiseaseWithdrawnNCT05471492Phase 2
Sponsor listed in the registry: Telavant, Inc. · First submitted before Telavant, Inc. became part of Hoffmann-La Roche
- Evaluation of Safety, Tolerability and Pharmacokinetics of Single Dose of PF-06480605 in Japanese Healthy ParticipantsCompletedNCT04269538Phase 1
Sponsor listed in the registry: Telavant, Inc. · First submitted before Telavant, Inc. became part of Hoffmann-La Roche
- Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.CompletedNCT01989143Phase 1
Sponsor listed in the registry: Telavant, Inc. · First submitted before Telavant, Inc. became part of Hoffmann-La Roche